Supernus Pharmaceuticals (SUPN) PT Raised to $25 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Price: $28.15 --0%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Stifel analyst Annabel Samimy raised the price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $25.00 (from $23.00) while maintaining a Hold rating.
You May Also Be Interested In
- Piper Sandler Resumes Supernus Pharmaceuticals (SUPN) at Overweight
- KEC International Ltd (KECI:IN) PT Lowered to INR400 at Axis Capital Limited
- Petronet LNG Ltd. (PLNG:IN) PT Raised to INR325 at Axis Capital Limited
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
